Novartis is proud to once again rank #2 in the FORTUNE World's Most Admired Companies Pharmaceuticals Industry list.
Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
For media and journalist inquiries, please contact the Novartis Corporate Media Relations office by email or telephone.
Central Media Line:Phone: +41 61 324 2200
This site is intended for a global audience.